ライフサイエンスコーパス: mucosal immune response

1 the antigen presentation process during this mucosal immune response.

2 the ongoing inflammation associated with the mucosal immune response.

3 obacter pylori infection causes a Th1-driven mucosal immune response.

4 ytes into the stomach and the launching of a mucosal immune response.

5 nterferon (IFN), a cytokine important in the mucosal immune response.

6 d is not the optimum route for stimulating a mucosal immune response.

7 dogenous IL-10 is a central regulator of the mucosal immune response.

8 e is the dominant site for the initiation of mucosal immune response.

9 ant vaccination site to produce a protective mucosal immune response.

10 -6/CCR-9, both in T cell development and the mucosal immune response.

11 he induction of both a systemic and a common mucosal immune response.

12 unctioned as specific stimuli for the infant mucosal immune response.

13 strategy stimulated a balanced systemic and mucosal immune response.

14 tranasal dosing uniquely stimulated a strong mucosal immune response.

15 messenger RNA (mRNA) vaccination to induce a mucosal immune response.

16 n of SARS-CoV-2 viral load with upper airway mucosal immune response.

17 ease (IBD) is associated with a dysregulated mucosal immune response.

18 tiology that are associated with an aberrant mucosal immune response.

19 innate and specific, which organise the host mucosal immune response.

20 the microbiome, which is known to influence mucosal immune responses.

21 an support trinitrophenyl (TNP)-LPS-specific mucosal immune responses.

22 sting that HIV-1 vaccines may need to elicit mucosal immune responses.

23 l antigen delivery typically fails to induce mucosal immune responses.

24 by CD4+ T cells dictates the outcome of the mucosal immune responses.

25 detailed analysis of humoral, cellular, and mucosal immune responses.

26 ctococcal vaccines for inducing systemic and mucosal immune responses.

27 h the mucoadhesive polymer chitosan enhances mucosal immune responses.

28 tive bacteria and are active participants in mucosal immune responses.

29 (Th2) that generate cytokines implicated in mucosal immune responses.

30 rds the generation of cellular, humoral, and mucosal immune responses.

31 sized to target IgA plasma cells involved in mucosal immune responses.

32 K/RANKL interactions during the induction of mucosal immune responses.

33 ntegrated yet distinct nature of systemic vs mucosal immune responses.

34 2 may be a simple way to augment tolerogenic mucosal immune responses.

35 transfer model of Th1- and Th2-mediated lung mucosal immune responses.

36 cule, transferrin, can significantly enhance mucosal immune responses.

37 the critical first step in the induction of mucosal immune responses.

38 ining the integrity of the epithelium and in mucosal immune responses.

39 iological processes as well as in regulating mucosal immune responses.

40 tinal epithelial cell (IEC) participation in mucosal immune responses.

41 ggesting that protection was due to specific mucosal immune responses.

42 l cells (IEC) as antigen-presenting cells in mucosal immune responses.

43 us, gp180 appears to be a novel regulator of mucosal immune responses.

44 toxin (CT) is a potent adjuvant for inducing mucosal immune responses.

45 an effective means of inducing systemic and mucosal immune responses.

46 y regulate the entry of antigen required for mucosal immune responses.

47 tribution of MC in boosting the Th17 axis in mucosal immune responses.

48 such as influenza viruses with induction of mucosal immune responses.

49 severity but do not efficiently induce local mucosal immune responses.

50 tor (GLP-1R) signaling network that controls mucosal immune responses.

51 enhance envelope (Env)-specific humoral and mucosal immune responses.

52 nic NP platforms engender potent humoral and mucosal immune responses.

53 ely poor in generating potent and long-lived mucosal immune responses.

54 djuvants for vaccines to induce systemic and mucosal immune responses.

55 d for disease progression, HIV shedding, and mucosal immune responses.

56 epithelial cells, colonic inflammation, and mucosal immune responses.

57 e in the control of T cell activation during mucosal immune responses.

58 g CD69 plays an important role in regulating mucosal immune responses.

59 was ubiquitously expressed on cells vital to mucosal immune responses.

60 minths influence intestinal inflammation and mucosal immune responses.

61 We aimed to investigate the role of CD69 in mucosal immune responses.

62 o in regulating both metabolic processes and mucosal immune responses.

63 ude vaccines that elicit durable, protective mucosal immune responses.

64 n pre-determining the type and robustness of mucosal immune responses.

65 C and CD4(+) T cells via TL, which modulates mucosal immune responses.

66 ucosal immunization can better educate these mucosal immune responses.

67 onships and role of NK and LTi-like cells in mucosal immune responses.

68 ort to develop vaccines capable of eliciting mucosal immune responses.

69 of the intestinal epithelium is critical for mucosal immune responses.

70 mmediate-early-gene expression in regulating mucosal immune responses.

71 , would be expected to decrease their ocular mucosal immune responses.

72 ation, in general, does not induce effective mucosal immune responses, a mucosal HIV vaccine is urgen

73 ural exposure to pneumococci or have altered mucosal immune responses after colonization with this or

74 nd exogenous IL-12 significantly augment the mucosal immune response against the intracellular pathog

75 icrobes and may play a role in initiation of mucosal immune responses against commensal or transient

76 via a bacterial adjuvant that may potentiate mucosal immune responses against deadly pathogens.

77 he sympathetic nervous system and alphaAR in mucosal immune responses against enteric bacterial patho

78 ts and vaccine delivery mechanisms to induce mucosal immune responses against key bacterial antigens

79 e required for generation of protective lung mucosal immune responses against microbial pathogens.

80 hen given orally to induce both systemic and mucosal immune responses against poliovirus has resulted

81 (F) protein, understanding the importance of mucosal immune responses against RSV infection, and the

82 ective in eliciting the production of both a mucosal immune response and a systemic bactericidal anti

83 olonic inflammation caused by a dysregulated mucosal immune response and epithelial barrier disruptio

84 ndings highlight the intrinsic compromise in mucosal immune response and have important implications

85 There was no significant correlation between mucosal immune response and most clinical factors.

86 gen sampling cells are known to initiate the mucosal immune response and to act as a site of entry fo

87 intestinal disease but can broadly activate mucosal immune responses and accelerate the onset and se

88 PBMC) populations were monitored weekly, and mucosal immune responses and bacterial loads were assess

89 le in antimicrobial and anticancer immunity, mucosal immune responses and effector functions of these

90 Mucosal immune responses and epithelial barrier function

91 a baseline for future studies on respiratory mucosal immune responses and for the development of muco

92 Defining mucosal immune responses and inflammation to candidate h

93 Because of their similarities to infants in mucosal immune responses and their susceptibility to hum

94 inoic acid administration fully restored the mucosal immune responses and vaccine protective efficacy

95 FMT on microbiota composition and function, mucosal immune response, and clinical outcome in patient

96 n-specific CD4(+) and CD8(+) T cells, primed mucosal immune responses, and enhanced protection from l

97 l factors in the gastrointestinal ecosystem, mucosal immune responses, and environmental factors.

98 assively acquired antibodies, the active gut mucosal immune responses, and immunoglobulin A (IgA) coa

99 CCR5 coreceptor by HIV; 4) CTL activity; 5) mucosal immune responses; and 6) CD8 T cell responses th

100 Local mucosal immune responses are critical for protection fro

101 However, we demonstrate in this article that mucosal immune responses are evident at multiple mucosal

102 is process and how fibroblasts contribute to mucosal immune responses are incompletely understood.

103 The strongest mucosal immune responses are induced following mucosal A

104 mental systems have been identified in which mucosal immune responses are induced following nonmucosa

105 We demonstrate that cellular and mucosal immune responses are pivotal correlates of cross

106 Protective mucosal immune responses are thought best induced by tra

107 tion and vaccine formulation on cellular and mucosal immune responses are undetermined.

108 hoid follicles, inductive sites for adaptive mucosal immune responses, are covered by a follicle-asso

109 ch underscores the importance of harmonizing mucosal immune response assays to evaluate new mucosal v

110 den of disease in humans has been redefined, mucosal immune responses associated with protection iden

111 ation and colitogenic microbiota transfer on mucosal immune responses at the intestinal barrier.

112 Mucosal immune responses at the URT provide the first li

113 t IBD is indeed characterized by an abnormal mucosal immune response but that microbial factors and e

114 ines and chemokines, which not only regulate mucosal immune responses but also regulate inflammatory

115 vaccine (IPV) does not induce an intestinal mucosal immune response, but could boost protection in c

116 Intestinal microbes induce homeostatic mucosal immune responses, but can also cause inappropria

117 - or anti-inflammatory roles in facilitating mucosal immune responses, but the relative contributions

118 by intramuscular (i.m.) injection can drive mucosal immune responses, but there are data suggesting

119 rance to OVA in mice primed for a Th2-biased mucosal immune response by infection with the nematode p

120 of water and electrolytes and modulates the mucosal immune response by stimulating cellular synthesi

121 s and had strong evidence of anti-Salmonella mucosal immune responses by enzyme-linked immunospot stu

122 One strategy for the induction of mucosal immune responses by oral immunization is to admi

123 ht to evaluate the induction of systemic and mucosal immune responses by the use of Newcastle disease

124 Infants mounted a robust mucosal immune response characterized by inflammatory cy

125 In a mouse model, Giardia induced a Type 2 mucosal immune response, characterized by antigen-specif

126 inflammasome forming NLRs that modulate the mucosal immune response during inflammatory bowel diseas

127 of H1N1 influenza virus and associated host mucosal immune responses during acute infection in human

128 ified PAC modulated pulmonary and intestinal mucosal immune responses during infection with the helmi

129 es, avidities, and functions of systemic and mucosal immune responses elicited by a vaccine regimen c

130 es that OMP CD is a target of a systemic and mucosal immune response following infection and coloniza

131 e response to goat anti-mouse IgD Ab and the mucosal immune response following oral inoculation with

132 Mucosal immune responses following liposome delivery to

133 ve intracellular bacterium, to study the gut mucosal immune responses following oral infection.

134 against a mucosal pathogen promotes stronger mucosal immune responses following prior mucosal infecti

135 Humans develop an array of mucosal immune responses following S. Typhi infection.

136 data underscore the importance of evaluating mucosal immune responses for better therapeutics and vac

137 cyte supernatant (ALS, a surrogate marker of mucosal immune responses) from patients with severe chol

138 Studying vaccine-elicited mucosal immune responses has been problematic because of

139 e COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-gamma, CXCL10, and CXCL13)

140 Cholera toxin (CT) elicits a mucosal immune response in mice when used as a vaccine a

141 suggest that EBV manipulates and evades the mucosal immune response in oral epithelial infection.

142 ganism, could induce an anatomically distant mucosal immune response in reproductive tract tissues, t

143 y to accentuate the development of a humoral mucosal immune response in the gut, and we used oral col

144 The exact role of the mucosal immune response in the pathogenesis of human pap

145 viable model for future investigation of the mucosal immune response in the RALT and its relationship

146 used by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that ma

147 Mucosal immune response in the upper respiratory tract i

148 that IL-10 is an important regulator of the mucosal immune response in vivo.

149 e relationships between specific species and mucosal immune responses in 'type-2 low', neutrophilic a

150 l tolerated, and induces robust systemic and mucosal immune responses in adults up to 80 years old.

151 G ODN) as a combined nasal adjuvant elicited mucosal immune responses in aged (2-y-old) mice.

152 but also as central drivers of dysregulated mucosal immune responses in asthma.

153 rtant for optimizing induction of anti-HIV-1 mucosal immune responses in both males and females.

154 s associations between microbial changes and mucosal immune responses in BV patients.

155 Importantly, prominent mucosal immune responses in CCR7-deficient mice increase

156 hese cells remains unclear, we have compared mucosal immune responses in gamma/delta T cell receptor-

157 In this analysis, we evaluated intestinal mucosal immune responses in healthy participants of diff

158 s variable levels of protective systemic and mucosal immune responses in humans and other animals.

159 HIV-1 Env vaccine elicited both systemic and mucosal immune responses in humans.

160 ARS-CoV-2 vaccine given peripherally boosted mucosal immune responses in infected persons, the increa

161 provide important measures of HIV-1-specific mucosal immune responses in infected women.

162 binant protein, known to induce systemic and mucosal immune responses in mammalian systems, has been

163 bust antigen-specific cellular, humoral, and mucosal immune responses in many animal models of infect

164 n induced long-lived protective systemic and mucosal immune responses in mice when administered in th

165 stalk- and virus-specific serum antibody and mucosal immune responses in mice, protecting against het

166 gen was evaluated to induce the systemic and mucosal immune responses in mice.

167 vitro in addition to improving systemic and mucosal immune responses in mice.

168 bacteria stimulate protective or tolerogenic mucosal immune responses in normal (ie, resistant) hosts

169 n be used to stimulate strong virus-specific mucosal immune responses in primates.

170 -I agonist (IVT) induces potent systemic and mucosal immune responses in protein-based SARS-CoV-2 vac

171 The ability to generate specific mucosal immune responses in reproductive tract tissues a

172 strategy that aims to induce the protective mucosal immune responses in the airway is urgently neede

173 erate with lymphocytes in the development of mucosal immune responses in the gastrointestinal tract.

174 sponse appears to underlie disruption of the mucosal immune responses in the genital tract of patient

175 d arthritis (RA) proposes a central role for mucosal immune responses in the initiation or perpetuati

176 Cs as a specialized FRC niche at the core of mucosal immune responses in the oropharynx.

177 the attractive property of inducing desired mucosal immune responses, including colostral antibodies

178 Generation of mucosal immune responses, including mucosal IgA, could b

179 cine additionally induces robust respiratory mucosal immune responses, including SARS-CoV-2-reactive

180 stemic immunity, robust humoral and cellular mucosal immune responses, including spike-specific IgA a

181 This study compares intestinal mucosal immune responses induced by nOPV2 and mOPV2.

182 no evidence of differences in the intestinal mucosal immune responses induced by nOPV2 or Sabin mOPV2

183 In this study, we sought to explore how mucosal immune responses influence HIF-dependent end poi

184 The gastric mucosal immune response is thought to be comprised predo

185 osal transmission, induction of an effective mucosal immune response is thought to be pivotal in prev

186 Induction of lung mucosal immune responses is highly desirable for vaccine

187 ular analysis of induction and regulation of mucosal immune responses, little is yet known about diff

188 t with a role for this pathway in generating mucosal immune responses, lung DC targeting by i.n. immu

189 Because mucosal immune responses may be important in protection

190 Early mucosal immune responses may define the trajectory of se

191 viral recovery on the LAIV-induced serum and mucosal immune responses, measured between days 0 and 21

192 ty with optimal induction of systemic and/or mucosal immune responses most appropriate for a particul

193 t that certain components of the innate oral mucosal immune response, most notably TLRs and inflammat

194 the plant tissues were simply fed to mice, a mucosal immune response occurred.

195 The mucosal immune response of the urinary bladder to bacter

196 As a surrogate to compare mucosal immune responses of infant and adult lungs, rhes

197 s conducted to evaluate cellular and humoral mucosal immune responses of pigs infected with porcine e

198 iggers a Mycobacterium tuberculosis-specific mucosal immune response orchestrated by interleukin 17A

199 onse but also to the cell-mediated and local mucosal immune responses, particularly in naive ferrets.

200 ection impairs the IL-17 axis, an arm of the mucosal immune response preventing systemic microbial di

201 rized and potentially linked to an efficient mucosal immune response, preventing colonization.

202 /- mice had decreased mucin production and a mucosal immune response profile suggestive of increased

203 To study whether cruzipain could induce mucosal immune responses relevant for vaccine developmen

204 ntibodies (NAbs), but their ability to boost mucosal immune responses remains to be determined.

205 But whether or how this process controls mucosal immune responses remains unknown.

206 The identification of mucosal immune responses required for protection against

207 nal microbiota, mucus layer, bile acids, and mucosal immune responses, reveal potential mechanisms by

208 a, via a global T-helper type 2 (Th2)-biased mucosal immune response secondary to STH infection.

209 ric microflora are driving forces regulating mucosal immune responses, some of which are pathogenic a

210 The mucosal immune responses stimulated by T. cruzi gastric

211 .m. route induced a more potent systemic and mucosal immune response than a single immunization by ei

212 induces changes in the microbiota and in the mucosal immune response that can be beneficial to the ho

213 nd/or B7-2 ligand interactions on the type 2 mucosal immune response that follows oral infection of m

214 CD40/CD40 ligand interactions on the type 2 mucosal immune response that follows oral inoculation of

215 n of anti-CD3 to mice induces changes in the mucosal immune response that prevent colitis, independen

216 r O157 can induce O157-specific cellular and mucosal immune responses that may be an important consid

217 accines have the advantage of inducing local mucosal immune responses that may block infection and in

218 three mutant enterotoxins potentiated strong mucosal immune responses that were equivalent to the res

219 In the context of mucosal immune responses, the integrin alpha 4 beta 7 ha

220 by which IL-4 could amplify inflammation in mucosal immune responses through receptor systems for en

221 ic susceptibility, intestinal microflora and mucosal immune responses through the pattern recognition

222 The mechanisms underlying this dysregulated mucosal immune response to a soluble antigen have not be

223 if humans would also develop a serum and/or mucosal immune response to an antigen delivered in an un

224 The role of leptin in the mucosal immune response to Clostridium difficile colitis

225 ranscriptomic changes that mediate the acute mucosal immune response to food allergens in EoE and sug

226 with DH originates from the small bowel as a mucosal immune response to gluten ingestion.

227 We hypothesized that the mucosal immune response to gluten is responsible for the

228 ained when OVA is fed during the peak of the mucosal immune response to H. polygyrus.

229 nt consequences for our understanding of the mucosal immune response to invasive pathogens.

230 important implications in understanding the mucosal immune response to M. catarrhalis in the setting

231 Major differences occur in the mucosal immune response to pathogens and commensals.

232 tions between enterocytes, and enhancing the mucosal immune response to pathogens.

233 we will share what we have learned about the mucosal immune response to SARS-CoV-2 and to COVID-19 va

234 Overall, our data show that the early nasal mucosal immune response to SARS-CoV-2 infection is viral

235 Our data suggest that early nasal mucosal immune response to SARS-CoV-2 infection was vira

236 Defensins are part of the innate mucosal immune response to STIs and therefore we investi

237 ry bowel disease is caused by a dysregulated mucosal immune response to the intestinal microflora in

238 sults from an aberrant and poorly understood mucosal immune response to the microbiota of the gastroi

239 mmensal interaction, indirectly via the host mucosal immune response to the pathogen, or by a combina

240 Mucosal immune response to the SARS-CoV-2 Spike protein

241 Here we examined the mouse mucosal immune responses to 12 filamentous environmental

242 ed clinical trial, we evaluated systemic and mucosal immune responses to a candidate adenovirus serot

243 show that nasal nCT as an adjuvant enhances mucosal immune responses to a T cell-independent Ag due

244 r future studies evaluating pathogenesis and mucosal immune responses to a variety of respiratory pat

245 ized approaches to attenuate the respiratory mucosal immune responses to air pollution.

246 ity are believed to be sites of induction of mucosal immune responses to airborne antigens.

247 nized by V cholerae and develop systemic and mucosal immune responses to antigens expressed by these

248 ial cavity to aquatic pathogens causes local mucosal immune responses to be extremely important for t

249 inistered vaccines induced both systemic and mucosal immune responses to coadministered Ags.

250 f-concept that diet and microbiota influence mucosal immune responses to CT vaccination and identify

251 parasite-specific cell-mediated and humoral mucosal immune responses to determine what constitutes p

252 Mucosal immune responses to enteric bacterial infections

253 Mucosal immune responses to fungal infection range from

254 rectal mucosa has led to intensive study of mucosal immune responses to HIV and to the development o

255 choma pathogenesis, no studies have examined mucosal immune responses to hsp60 in populations for whi

256 t cells of ZIKV infection and the subsequent mucosal immune responses to infection, and we demonstrat

257 ng of the importance of IL-10 in controlling mucosal immune responses to infectious challenges, we em

258 We characterized the role of Card9 in mucosal immune responses to intestinal epithelial injury

259 mouse model that permits the study of human mucosal immune responses to lung pathogens.

260 Mucosal immune responses to meningococcal conjugate and

261 nvasive mucosal samples provide insight into mucosal immune responses to microbial and noxious elemen

262 sid protein (VRP-NV1) developed systemic and mucosal immune responses to Norwalk VLPs, as well as het

263 d with VRP-NV2 elicited reduced systemic and mucosal immune responses to Norwalk VLPs, demonstrating

264 Hence, eliciting mucosal immune responses to pathobiont surface component

265 Mucosal immune responses to pathogenic gut bacteria and

266 given mucosally, on the systemic and distal mucosal immune responses to plasmid DNA encoding gB of h

267 nce of IL-12 is able to enhance systemic and mucosal immune responses to pneumococci and efficiently

268 deeper understanding of the dysregulation of mucosal immune responses to the commensal intestinal org

269 To optimize mucosal immune responses to the HIV-1 peptide vaccine ca

270 essentially no studies to date have assessed mucosal immune responses to this disease.

271 The means by which mucosal immune responses to vaccine antigens are elicite

272 uring highly T helper 1 (Th1) cell-polarized mucosal immune responses, Treg cell numbers collapsed vi

273 stigates perturbation of the host intestinal mucosal immune response, using a model of human microbio

274 owever, despite their critical importance in mucosal immune responses, very little is known about the

275 spike-specific antibodies in serum, and the mucosal immune response was assessed by measuring specif

276 The mucosal immune response was assessed by measuring spike-

277 The mucosal immune response was characterized by morphometri

278 (CCR6) deficiency affects the generation of mucosal immune responses, we evaluated a potential role

279 n as mucosal adjuvant, and both systemic and mucosal immune responses were assessed.

280 sally immunized with cholera toxin (CT), and mucosal immune responses were compared with C57BL/6 mice

281 asal immunizations of guinea pigs, serum and mucosal immune responses were detected against both Shig

282 Anti-CFA/II mucosal immune responses were determined from the number

283 Serological and mucosal immune responses were evaluated in all vaccinate

284 The humoral and mucosal immune responses were further augmented if both

285 Increased antigen-specific mucosal immune responses were induced in the lungs and t

286 No mucosal immune responses were measurable when the immuno

287 , while CD8(+) T-cell antiviral activity and mucosal immune responses were not associated with delaye

288 Systemic and mucosal immune responses were robust in naive subjects i

289 hat these mice generated an intimin-specific mucosal immune response when primed parenterally and the

290 A) has shown great promise in activating the mucosal immune response with minimal impacts on the resi

291 s to induce protective as well as pathogenic mucosal immune responses, with the type of response depe

292 Our studies reveal compartmentalized mucosal immune responses within the nasal mucosa of a ve